Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(57.1%)
Phase 3
3(42.9%)
7Total
N/A(4)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT01542606Not ApplicableWithdrawn

Performance Proof of Product Developed to Detect Abnormal Vaginal pH

Role: lead

NCT02959268Not ApplicableCompleted

Pivotal Study of the Rx Al-Sense Liner for Amniotic Fluid Leakage Screening

Role: lead

NCT02965430Phase 3Completed

PERFORMANCE STUDY OF THE AL-SENSE

Role: lead

NCT03190434Completed

Pivotal Study of the AL-SENSE in Diagnosis Amniotic Fluid Leakage

Role: lead

NCT03177135Not ApplicableUnknown

PROOF OF AMNIOSENSE BLUE IN HOME USAGE AND HOSPITAL

Role: lead

NCT01804348Not ApplicableUnknown

AL-SENSE 1-Step - Determination of Product Specificity

Role: lead

NCT00491270Phase 3Unknown

Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery

Role: collaborator

NCT01152528Phase 3Unknown

Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery

Role: lead

NCT00803127Completed

VS-Sense Result Reading Clarity

Role: collaborator

NCT00324246Completed

Feasibility Study of the NEW NORMA-SENSE

Role: collaborator

All 10 trials loaded